Meeting
2014 Gastrointestinal Cancers Symposium
Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.
Authors
Robert Lance Fine
Columbia University, New York, NY
Robert Lance Fine , Anthony Paul Gulati , Dawn Tsushima , Kelley B. Mowatt , Anna Oprescu , Jeffrey N. Bruce , John A. Chabot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT00869050
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 179)
DOI
10.1200/jco.2014.32.3_suppl.179
Abstract #
179
Poster Bd #
A8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
First Author: Jennifer Rachel Eads
Poster
2018 Gastrointestinal Cancers Symposium
Safety of trifluridine/tipiracil (TAS-102) in combination with temozolomide for metastatic neuroendocrine tumors.
First Author: Nataliya Volodymyrivna Uboha
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104.
First Author: Heloisa P. Soares
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of oral chemotherapy with capecitabine and temozolomide (CapTem) in metastatic neuroendocrine tumors (NETs): A single-institution experience.
First Author: Valeria Smiroldo